annual EBITDA:
$316.89M+$770.58M(+169.85%)Summary
- As of today (May 29, 2025), SRPT annual EBITDA is $316.89 million, with the most recent change of +$770.58 million (+169.85%) on December 31, 2024.
- During the last 3 years, SRPT annual EBITDA has risen by +$634.29 million (+199.84%).
- SRPT annual EBITDA is now at all-time high.
Performance
SRPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$369.04M-$555.71M(-297.69%)Summary
- As of today (May 29, 2025), SRPT quarterly EBITDA is -$369.04 million, with the most recent change of -$555.71 million (-297.69%) on March 1, 2025.
- Over the past year, SRPT quarterly EBITDA has dropped by -$423.39 million (-778.90%).
- SRPT quarterly EBITDA is now -297.69% below its all-time high of $186.67 million, reached on December 31, 2024.
Performance
SRPT quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$106.51M-$423.39M(-133.61%)Summary
- As of today (May 29, 2025), SRPT TTM EBITDA is -$106.51 million, with the most recent change of -$423.39 million (-133.61%) on March 1, 2025.
- Over the past year, SRPT TTM EBITDA has dropped by -$202.25 million (-211.23%).
- SRPT TTM EBITDA is now -133.61% below its all-time high of $316.89 million, reached on December 31, 2024.
Performance
SRPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SRPT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +169.8% | -778.9% | -211.2% |
| 3 y3 years | +199.8% | -375.4% | +57.8% |
| 5 y5 years | +148.1% | -10000.0% | +82.0% |
SRPT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +153.3% | -297.7% | +25.5% | -133.6% | +89.5% |
| 5 y | 5-year | at high | +148.1% | -297.7% | +25.5% | -133.6% | +89.5% |
| alltime | all time | at high | +148.1% | -297.7% | +25.5% | -133.6% | +89.5% |
SRPT EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$369.04M(-297.7%) | -$106.51M(-133.6%) |
| Dec 2024 | $316.89M(-169.8%) | $186.67M(+283.1%) | $316.89M(+69.3%) |
| Sep 2024 | - | $48.73M(+79.6%) | $187.19M(+54.1%) |
| Jun 2024 | - | $27.13M(-50.1%) | $121.45M(+26.8%) |
| Mar 2024 | - | $54.36M(-4.6%) | $95.75M(-121.1%) |
| Dec 2023 | -$453.69M(-23.7%) | $56.98M(-434.8%) | -$453.69M(-23.7%) |
| Sep 2023 | - | -$17.02M(-1289.2%) | -$594.73M(-26.5%) |
| Jun 2023 | - | $1.43M(-100.3%) | -$808.70M(-20.1%) |
| Mar 2023 | - | -$495.08M(+488.9%) | -$1.01B(+70.2%) |
| Dec 2022 | -$594.85M(+87.4%) | -$84.06M(-63.6%) | -$594.85M(-1.9%) |
| Sep 2022 | - | -$230.98M(+14.2%) | -$606.48M(+52.8%) |
| Jun 2022 | - | -$202.18M(+160.4%) | -$396.92M(+57.4%) |
| Mar 2022 | - | -$77.63M(-18.9%) | -$252.22M(-20.5%) |
| Dec 2021 | -$317.41M(-31.9%) | -$95.70M(+346.8%) | -$317.41M(-17.4%) |
| Sep 2021 | - | -$21.42M(-62.7%) | -$384.18M(-28.7%) |
| Jun 2021 | - | -$57.48M(-59.8%) | -$538.65M(-12.0%) |
| Mar 2021 | - | -$142.81M(-12.1%) | -$611.79M(+31.2%) |
| Dec 2020 | -$466.21M(-29.2%) | -$162.47M(-7.6%) | -$466.21M(-11.0%) |
| Sep 2020 | - | -$175.90M(+34.7%) | -$523.70M(+13.9%) |
| Jun 2020 | - | -$130.61M(-4820.3%) | -$459.64M(-22.3%) |
| Mar 2020 | - | $2.77M(-101.3%) | -$591.60M(-10.2%) |
| Dec 2019 | -$658.71M(+108.0%) | -$219.96M(+96.7%) | -$658.71M(+15.6%) |
| Sep 2019 | - | -$111.84M(-57.4%) | -$569.65M(+9.4%) |
| Jun 2019 | - | -$262.57M(+308.1%) | -$520.61M(+46.4%) |
| Mar 2019 | - | -$64.34M(-50.8%) | -$355.66M(+12.3%) |
| Dec 2018 | -$316.66M(+811.6%) | -$130.90M(+108.5%) | -$316.66M(+54.5%) |
| Sep 2018 | - | -$62.79M(-35.7%) | -$205.00M(+11.1%) |
| Jun 2018 | - | -$97.63M(+285.3%) | -$184.57M(+24.7%) |
| Mar 2018 | - | -$25.34M(+31.7%) | -$148.06M(+326.2%) |
| Dec 2017 | -$34.73M(-86.6%) | -$19.24M(-54.6%) | -$34.74M(-65.8%) |
| Sep 2017 | - | -$42.36M(-30.7%) | -$101.51M(-11.4%) |
| Jun 2017 | - | -$61.12M(-169.5%) | -$114.61M(+0.5%) |
| Mar 2017 | - | $87.98M(-202.3%) | -$114.00M(-56.2%) |
| Dec 2016 | -$259.76M(+21.7%) | -$86.01M(+55.1%) | -$260.29M(+10.4%) |
| Sep 2016 | - | -$55.46M(-8.3%) | -$235.84M(+2.2%) |
| Jun 2016 | - | -$60.51M(+3.8%) | -$230.83M(+9.3%) |
| Mar 2016 | - | -$58.30M(-5.3%) | -$211.14M(-1.1%) |
| Dec 2015 | -$213.42M(+64.0%) | -$61.57M(+22.0%) | -$213.42M(+9.2%) |
| Sep 2015 | - | -$50.45M(+23.6%) | -$195.41M(+10.0%) |
| Jun 2015 | - | -$40.82M(-32.6%) | -$177.59M(+6.9%) |
| Mar 2015 | - | -$60.58M(+39.1%) | -$166.08M(+27.7%) |
| Dec 2014 | -$130.10M(+46.2%) | -$43.56M(+33.5%) | -$130.10M(+9.2%) |
| Sep 2014 | - | -$32.63M(+11.3%) | -$119.11M(+7.2%) |
| Jun 2014 | - | -$29.31M(+19.2%) | -$111.13M(+12.7%) |
| Mar 2014 | - | -$24.60M(-24.5%) | -$98.64M(+10.8%) |
| Dec 2013 | -$89.01M(+215.9%) | -$32.57M(+32.2%) | -$89.01M(+34.1%) |
| Sep 2013 | - | -$24.65M(+46.5%) | -$66.37M(+37.5%) |
| Jun 2013 | - | -$16.83M(+12.4%) | -$48.25M(+31.8%) |
| Mar 2013 | - | -$14.96M(+50.7%) | -$36.62M(+30.0%) |
| Dec 2012 | -$28.18M(-18.6%) | -$9.93M(+52.1%) | -$28.18M(+5.5%) |
| Sep 2012 | - | -$6.53M(+25.7%) | -$26.71M(-14.3%) |
| Jun 2012 | - | -$5.20M(-20.3%) | -$31.18M(-13.0%) |
| Mar 2012 | - | -$6.52M(-22.9%) | -$35.86M(+3.5%) |
| Dec 2011 | -$34.63M(+77.8%) | -$8.46M(-23.0%) | -$34.63M(+25.9%) |
| Sep 2011 | - | -$11.00M(+11.4%) | -$27.49M(+37.9%) |
| Jun 2011 | - | -$9.87M(+86.6%) | -$19.94M(+14.7%) |
| Mar 2011 | - | -$5.29M(+297.9%) | -$17.38M(-10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$19.47M(+37.8%) | -$1.33M(-61.4%) | -$19.48M(-10.7%) |
| Sep 2010 | - | -$3.44M(-53.0%) | -$21.81M(+4.2%) |
| Jun 2010 | - | -$7.32M(-1.0%) | -$20.93M(+14.2%) |
| Mar 2010 | - | -$7.39M(+101.9%) | -$18.32M(+29.7%) |
| Dec 2009 | -$14.13M(-12.1%) | -$3.66M(+42.8%) | -$14.13M(+9.2%) |
| Sep 2009 | - | -$2.56M(-45.6%) | -$12.94M(-19.0%) |
| Jun 2009 | - | -$4.71M(+47.2%) | -$15.97M(+1.1%) |
| Mar 2009 | - | -$3.20M(+29.5%) | -$15.79M(-1.8%) |
| Dec 2008 | -$16.07M(-48.3%) | -$2.47M(-55.8%) | -$16.07M(-14.3%) |
| Sep 2008 | - | -$5.59M(+23.4%) | -$18.77M(-11.3%) |
| Jun 2008 | - | -$4.53M(+30.1%) | -$21.15M(-15.3%) |
| Mar 2008 | - | -$3.48M(-32.5%) | -$24.97M(-19.7%) |
| Dec 2007 | -$31.09M(+0.7%) | -$5.16M(-35.3%) | -$31.09M(-9.0%) |
| Sep 2007 | - | -$7.97M(-4.5%) | -$34.17M(+3.7%) |
| Jun 2007 | - | -$8.35M(-13.1%) | -$32.95M(+4.6%) |
| Mar 2007 | - | -$9.61M(+16.5%) | -$31.50M(+2.0%) |
| Dec 2006 | -$30.89M(+99.1%) | -$8.24M(+22.1%) | -$30.89M(+14.3%) |
| Sep 2006 | - | -$6.75M(-2.3%) | -$27.03M(+24.5%) |
| Jun 2006 | - | -$6.91M(-23.2%) | -$21.70M(+11.6%) |
| Mar 2006 | - | -$8.99M(+105.6%) | -$19.45M(+25.3%) |
| Dec 2005 | -$15.52M(-33.0%) | -$4.38M(+206.9%) | -$15.52M(-0.3%) |
| Sep 2005 | - | -$1.43M(-69.4%) | -$15.56M(-19.2%) |
| Jun 2005 | - | -$4.66M(-8.0%) | -$19.26M(-11.8%) |
| Mar 2005 | - | -$5.06M(+14.6%) | -$21.83M(-9.4%) |
| Dec 2004 | -$23.16M(+33.2%) | -$4.42M(-13.8%) | -$24.10M(-8.7%) |
| Sep 2004 | - | -$5.12M(-29.2%) | -$26.38M(+3.1%) |
| Jun 2004 | - | -$7.23M(-1.3%) | -$25.59M(+18.7%) |
| Mar 2004 | - | -$7.32M(+9.3%) | -$21.57M(+24.0%) |
| Dec 2003 | -$17.39M(-27.6%) | -$6.70M(+54.8%) | -$17.39M(+20.3%) |
| Sep 2003 | - | -$4.33M(+34.9%) | -$14.46M(-4.6%) |
| Jun 2003 | - | -$3.21M(+1.9%) | -$15.15M(-22.4%) |
| Mar 2003 | - | -$3.15M(-16.6%) | -$19.53M(-18.7%) |
| Dec 2002 | -$24.01M(+61.7%) | -$3.77M(-24.9%) | -$24.01M(-2.9%) |
| Sep 2002 | - | -$5.02M(-33.7%) | -$24.73M(+7.8%) |
| Jun 2002 | - | -$7.58M(-0.6%) | -$22.93M(+20.5%) |
| Mar 2002 | - | -$7.63M(+69.7%) | -$19.03M(+28.2%) |
| Dec 2001 | -$14.85M(+51.1%) | -$4.50M(+39.3%) | -$14.85M(+9.0%) |
| Sep 2001 | - | -$3.23M(-12.2%) | -$13.62M(+5.6%) |
| Jun 2001 | - | -$3.68M(+6.6%) | -$12.90M(+6.6%) |
| Mar 2001 | - | -$3.45M(+5.4%) | -$12.10M(+23.2%) |
| Dec 2000 | -$9.82M(+22.8%) | -$3.27M(+30.6%) | -$9.82M(+12.3%) |
| Sep 2000 | - | -$2.50M(-13.0%) | -$8.75M(+4.8%) |
| Jun 2000 | - | -$2.88M(+146.6%) | -$8.35M(+13.3%) |
| Mar 2000 | - | -$1.17M(-46.9%) | -$7.37M(-4.3%) |
| Dec 1999 | -$8.00M(+5.3%) | -$2.20M(+4.8%) | -$7.70M(-4.9%) |
| Sep 1999 | - | -$2.10M(+10.5%) | -$8.10M(+5.2%) |
| Jun 1999 | - | -$1.90M(+26.7%) | -$7.70M(+4.1%) |
| Mar 1999 | - | -$1.50M(-42.3%) | -$7.40M(+1.4%) |
| Dec 1998 | -$7.60M(+123.5%) | -$2.60M(+52.9%) | -$7.30M(+32.7%) |
| Sep 1998 | - | -$1.70M(+6.3%) | -$5.50M(+17.0%) |
| Jun 1998 | - | -$1.60M(+14.3%) | -$4.70M(+14.6%) |
| Mar 1998 | - | -$1.40M(+75.0%) | -$4.10M(+28.1%) |
| Dec 1997 | -$3.40M(+100.0%) | -$800.00K(-11.1%) | -$3.20M(+33.3%) |
| Sep 1997 | - | -$900.00K(-10.0%) | -$2.40M(+60.0%) |
| Jun 1997 | - | -$1.00M(+100.0%) | -$1.50M(+200.0%) |
| Mar 1997 | - | -$500.00K | -$500.00K |
| Dec 1996 | -$1.70M | - | - |
FAQ
- What is Sarepta Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual EBITDA year-on-year change?
- What is Sarepta Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly EBITDA year-on-year change?
- What is Sarepta Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM EBITDA year-on-year change?
What is Sarepta Therapeutics annual EBITDA?
The current annual EBITDA of SRPT is $316.89M
What is the all time high annual EBITDA for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual EBITDA is $316.89M
What is Sarepta Therapeutics annual EBITDA year-on-year change?
Over the past year, SRPT annual EBITDA has changed by +$770.58M (+169.85%)
What is Sarepta Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SRPT is -$369.04M
What is the all time high quarterly EBITDA for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly EBITDA is $186.67M
What is Sarepta Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SRPT quarterly EBITDA has changed by -$423.39M (-778.90%)
What is Sarepta Therapeutics TTM EBITDA?
The current TTM EBITDA of SRPT is -$106.51M
What is the all time high TTM EBITDA for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM EBITDA is $316.89M
What is Sarepta Therapeutics TTM EBITDA year-on-year change?
Over the past year, SRPT TTM EBITDA has changed by -$202.25M (-211.23%)